Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes

Nicola J. Hewitt, Scott Lloyd, Mike Hayden, Ryan Butler, Yumiko Sakai, Ryan Springer, Andrew Fackett, Albert P. Li

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Troglitazone (TRO) was developed for the treatment of type II diabetes. It was withdrawn from use due to idiosyncratic liver damage and failure. The mechanism of toxicity is still not determined, moreover, it is still not clear whether toxicity is due to the parent compound or its metabolite(s). The cytotoxicity of TRO was evaluated in human hepatocytes using previously cryopreserved hepatocyte suspensions from 27 human donors. Cellular adenosine triphosphate content was used as a viability endpoint. To investigate the role of xenobiotic metabolism in TRO toxicity, the correlation between the drug metabolism activities of the hepatocytes from each donor to EC50 values TRO cytotoxicity. The activities examined were cytochrome P450 (CYP) isoform activities (CYP2A6, CYP2D6, CYP2C19, CYP1A2, CYP2E1, CYP3A4 and CYP2C9) and phase 2 conjugation enzyme activities (phenol sulfotransferase (PST) and glucuronyl transferase (UGT)). Taken individually, none of the phase 1 or 2 enzyme activities correlated to the EC50. However, when three enzyme activities ((CYP3A4×UGT)/PST) were taken into account, a correlation was made (r2=0.53). Based on the correlation, we hypothesize that TRO and TRO sulfate are direct acting toxicants, whereas CYP3A4 oxidation and glucuronidation are detoxification pathways.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalChemico-Biological Interactions
Volume142
Issue number1-2
DOIs
StatePublished - Nov 10 2002
Externally publishedYes

Fingerprint

troglitazone
Enzyme activity
Cytotoxicity
Hepatocytes
Arylsulfotransferase
Toxicity
Enzymes
Cytochrome P-450 CYP3A
Pharmaceutical Preparations
Metabolism
Cytochrome P-450 CYP2E1
Cytochrome P-450 CYP1A2
Cytochrome P-450 CYP2D6
Detoxification
Liver Failure
Xenobiotics
Medical problems
Transferases
Metabolites
Liver

Keywords

  • Cytotoxicity
  • Drug metabolism
  • Hepatotoxicity
  • Human hepatocytes
  • P450
  • Troglitazone

ASJC Scopus subject areas

  • Toxicology

Cite this

Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. / Hewitt, Nicola J.; Lloyd, Scott; Hayden, Mike; Butler, Ryan; Sakai, Yumiko; Springer, Ryan; Fackett, Andrew; Li, Albert P.

In: Chemico-Biological Interactions, Vol. 142, No. 1-2, 10.11.2002, p. 73-82.

Research output: Contribution to journalArticle

Hewitt, Nicola J. ; Lloyd, Scott ; Hayden, Mike ; Butler, Ryan ; Sakai, Yumiko ; Springer, Ryan ; Fackett, Andrew ; Li, Albert P. / Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. In: Chemico-Biological Interactions. 2002 ; Vol. 142, No. 1-2. pp. 73-82.
@article{038809b5247847e4bdc8f3cdded59e11,
title = "Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes",
abstract = "Troglitazone (TRO) was developed for the treatment of type II diabetes. It was withdrawn from use due to idiosyncratic liver damage and failure. The mechanism of toxicity is still not determined, moreover, it is still not clear whether toxicity is due to the parent compound or its metabolite(s). The cytotoxicity of TRO was evaluated in human hepatocytes using previously cryopreserved hepatocyte suspensions from 27 human donors. Cellular adenosine triphosphate content was used as a viability endpoint. To investigate the role of xenobiotic metabolism in TRO toxicity, the correlation between the drug metabolism activities of the hepatocytes from each donor to EC50 values TRO cytotoxicity. The activities examined were cytochrome P450 (CYP) isoform activities (CYP2A6, CYP2D6, CYP2C19, CYP1A2, CYP2E1, CYP3A4 and CYP2C9) and phase 2 conjugation enzyme activities (phenol sulfotransferase (PST) and glucuronyl transferase (UGT)). Taken individually, none of the phase 1 or 2 enzyme activities correlated to the EC50. However, when three enzyme activities ((CYP3A4×UGT)/PST) were taken into account, a correlation was made (r2=0.53). Based on the correlation, we hypothesize that TRO and TRO sulfate are direct acting toxicants, whereas CYP3A4 oxidation and glucuronidation are detoxification pathways.",
keywords = "Cytotoxicity, Drug metabolism, Hepatotoxicity, Human hepatocytes, P450, Troglitazone",
author = "Hewitt, {Nicola J.} and Scott Lloyd and Mike Hayden and Ryan Butler and Yumiko Sakai and Ryan Springer and Andrew Fackett and Li, {Albert P.}",
year = "2002",
month = "11",
day = "10",
doi = "10.1016/S0009-2797(02)00055-8",
language = "English (US)",
volume = "142",
pages = "73--82",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes

AU - Hewitt, Nicola J.

AU - Lloyd, Scott

AU - Hayden, Mike

AU - Butler, Ryan

AU - Sakai, Yumiko

AU - Springer, Ryan

AU - Fackett, Andrew

AU - Li, Albert P.

PY - 2002/11/10

Y1 - 2002/11/10

N2 - Troglitazone (TRO) was developed for the treatment of type II diabetes. It was withdrawn from use due to idiosyncratic liver damage and failure. The mechanism of toxicity is still not determined, moreover, it is still not clear whether toxicity is due to the parent compound or its metabolite(s). The cytotoxicity of TRO was evaluated in human hepatocytes using previously cryopreserved hepatocyte suspensions from 27 human donors. Cellular adenosine triphosphate content was used as a viability endpoint. To investigate the role of xenobiotic metabolism in TRO toxicity, the correlation between the drug metabolism activities of the hepatocytes from each donor to EC50 values TRO cytotoxicity. The activities examined were cytochrome P450 (CYP) isoform activities (CYP2A6, CYP2D6, CYP2C19, CYP1A2, CYP2E1, CYP3A4 and CYP2C9) and phase 2 conjugation enzyme activities (phenol sulfotransferase (PST) and glucuronyl transferase (UGT)). Taken individually, none of the phase 1 or 2 enzyme activities correlated to the EC50. However, when three enzyme activities ((CYP3A4×UGT)/PST) were taken into account, a correlation was made (r2=0.53). Based on the correlation, we hypothesize that TRO and TRO sulfate are direct acting toxicants, whereas CYP3A4 oxidation and glucuronidation are detoxification pathways.

AB - Troglitazone (TRO) was developed for the treatment of type II diabetes. It was withdrawn from use due to idiosyncratic liver damage and failure. The mechanism of toxicity is still not determined, moreover, it is still not clear whether toxicity is due to the parent compound or its metabolite(s). The cytotoxicity of TRO was evaluated in human hepatocytes using previously cryopreserved hepatocyte suspensions from 27 human donors. Cellular adenosine triphosphate content was used as a viability endpoint. To investigate the role of xenobiotic metabolism in TRO toxicity, the correlation between the drug metabolism activities of the hepatocytes from each donor to EC50 values TRO cytotoxicity. The activities examined were cytochrome P450 (CYP) isoform activities (CYP2A6, CYP2D6, CYP2C19, CYP1A2, CYP2E1, CYP3A4 and CYP2C9) and phase 2 conjugation enzyme activities (phenol sulfotransferase (PST) and glucuronyl transferase (UGT)). Taken individually, none of the phase 1 or 2 enzyme activities correlated to the EC50. However, when three enzyme activities ((CYP3A4×UGT)/PST) were taken into account, a correlation was made (r2=0.53). Based on the correlation, we hypothesize that TRO and TRO sulfate are direct acting toxicants, whereas CYP3A4 oxidation and glucuronidation are detoxification pathways.

KW - Cytotoxicity

KW - Drug metabolism

KW - Hepatotoxicity

KW - Human hepatocytes

KW - P450

KW - Troglitazone

UR - http://www.scopus.com/inward/record.url?scp=0037058255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037058255&partnerID=8YFLogxK

U2 - 10.1016/S0009-2797(02)00055-8

DO - 10.1016/S0009-2797(02)00055-8

M3 - Article

C2 - 12399156

AN - SCOPUS:0037058255

VL - 142

SP - 73

EP - 82

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 1-2

ER -